178 related articles for article (PubMed ID: 28803748)
1. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Holcomb K
Gynecol Oncol; 2017 Nov; 147(2):296-301. PubMed ID: 28803748
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
de la Motte Rouge T; Pautier P; Genestie C; Rey A; Gouy S; Leary A; Haie-Meder C; Kerbrat P; Culine S; Fizazi K; Lhommé C
Gynecol Oncol; 2016 Sep; 142(3):452-7. PubMed ID: 27401840
[TBL] [Abstract][Full Text] [Related]
3. Ovarian Yolk Sac Tumors; Does Age Matter?
Faure Conter C; Xia C; Gershenson D; Hurteau J; Covens A; Pashankar F; Krailo M; Billmire D; Patte C; Fresneau B; Shaikh F; Stoneham S; Nicholson J; Murray M; Frazier AL
Int J Gynecol Cancer; 2018 Jan; 28(1):77-84. PubMed ID: 29194189
[TBL] [Abstract][Full Text] [Related]
4. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
[TBL] [Abstract][Full Text] [Related]
5. Trends in the surgical management of malignant ovarian germcell tumors.
Nasioudis D; Mastroyannis SA; Latif NA; Ko EM
Gynecol Oncol; 2020 Apr; 157(1):89-93. PubMed ID: 32008791
[TBL] [Abstract][Full Text] [Related]
6. Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb K
Gynecol Oncol; 2017 Dec; 147(3):493-496. PubMed ID: 29021083
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases.
Boyraz G; Durmus Y; Cicin I; Kuru O; Bostanci E; Comert GK; Sahin H; Ayik H; Ureyen I; Karalok A; Meydanli MM; Salman MC; Ozgul N; Onan A; Simsek T; Yuce K; Turan T
Arch Gynecol Obstet; 2019 Jul; 300(1):175-182. PubMed ID: 30982145
[TBL] [Abstract][Full Text] [Related]
8. Primary malignant ovarian carcinoid; management and outcomes.
Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb K
Gynecol Oncol; 2020 Apr; 157(1):101-105. PubMed ID: 31959493
[TBL] [Abstract][Full Text] [Related]
9. Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis.
Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Int J Gynecol Cancer; 2018 Jun; 28(5):932-938. PubMed ID: 29621125
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Yolk Sac Tumor: The Experience of a Regional Cancer Center.
Wang X; Ma Z; Li Y
Int J Gynecol Cancer; 2016 Jun; 26(5):884-91. PubMed ID: 27104939
[TBL] [Abstract][Full Text] [Related]
11. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of patients with ovarian yolk sac tumors: a study in Chinese patients.
Tong X; You Q; Li L; Cai L; Wang C; Zheng J
Onkologie; 2008 Dec; 31(12):679-84. PubMed ID: 19060506
[TBL] [Abstract][Full Text] [Related]
13. Surveillance Only for High-risk FIGO Stage IA/IB Malignant Ovarian Germ Cell Tumors: Results From a National Cancer Database.
Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb KM
Am J Clin Oncol; 2021 May; 44(5):195-199. PubMed ID: 33710136
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of patients with yolk sac tumors of the ovary.
Nawa A; Obata N; Kikkawa F; Kawai M; Nagasaka T; Goto S; Nishimori K; Nakashima N
Am J Obstet Gynecol; 2001 May; 184(6):1182-8. PubMed ID: 11349186
[TBL] [Abstract][Full Text] [Related]
15. Endodermal sinus tumor of the ovary: the Hacettepe University experience.
Ayhan A; Taskiran C; Bozdag G; Altinbas S; Altinbas A; Yuce K
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):230-4. PubMed ID: 16026921
[TBL] [Abstract][Full Text] [Related]
16. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?
Rittiluechai K; Wilcox R; Lisle J; Everett E; Wallace HJ; Verschraegen CF
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():25-9. PubMed ID: 24462393
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
Nasioudis D; Kanninen TT; Holcomb K; Sisti G; Witkin SS
Gynecol Oncol; 2017 May; 145(2):243-247. PubMed ID: 28292524
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy and Delivery After Ovarian Yolk Sac Tumor: A Case Report.
Alrjoub MM; Sindiani A; Alshriedeh O; Amarin Z
Am J Case Rep; 2021 Aug; 22():e932091. PubMed ID: 34408122
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Characteristics and Survival of Patients with Rare Malignant Ovarian Yolk Sac Tumors: A Population-based Analysis.
Wang T; Wang B; Wang SX; Wu MF
Curr Med Sci; 2021 Apr; 41(2):342-347. PubMed ID: 33877552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
